Financial reports
10-K
2023 FY
Annual report
8 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
10-K
2022 FY
Annual report
16 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Apr 24
8-K
Entry into a Material Definitive Agreement
1 Apr 24
8-K
Departure of Directors or Certain Officers
11 Mar 24
8-K
Departure of Directors or Certain Officers
24 Jan 24
8-K
Material Modifications to Rights of Security Holders
8 Jan 24
8-K
Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split
4 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Nov 23
8-K
Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
8-K
Other Events
12 Sep 23
8-K
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
14 Aug 23
Registration and prospectus
25-NSE
Exchange delisting
25 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Apr 24
Proxies
DEF 14A
Definitive proxy
11 Dec 23
PRE 14A
Preliminary proxy
1 Dec 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
28 Apr 21
DEFA14A
Additional proxy soliciting materials
29 May 20
DEFA14A
Additional proxy soliciting materials
28 Apr 20
Other
EFFECT
Notice of effectiveness
4 Jan 21
CORRESP
Correspondence with SEC
28 Dec 20
UPLOAD
Letter from SEC
23 Dec 20
EFFECT
Notice of effectiveness
2 Jan 20
CORRESP
Correspondence with SEC
26 Dec 19
UPLOAD
Letter from SEC
23 Dec 19
CT ORDER
Confidential treatment order
20 Dec 18
CT ORDER
Confidential treatment order
20 Aug 18
EFFECT
Notice of effectiveness
20 Dec 17
CORRESP
Correspondence with SEC
15 Dec 17
Ownership
SC 13G/A
683 Capital Management, LLC
14 Feb 24
SC 13G/A
AMERIPRISE FINANCIAL INC
14 Feb 24
SC 13D/A
Arkin Moshe
4 Dec 23
SC 13D
Arkin Moshe
24 Nov 23
SC 13D/A
Propel Bio Management, LLC
2 Nov 23
4
RICHARD A KAYNE
2 Nov 23
4
LEEN KAWAS
2 Nov 23
3
RICHARD A KAYNE
30 Oct 23
3
LEEN KAWAS
30 Oct 23
SC 13D
Propel Bio Management, LLC
20 Oct 23